After US Approval, BeiGene Set To Gain Sixth PD-1 Green Light In China
But Is Sector Becoming Overcrowded?
Executive Summary
Beijing-based BeiGene is set to score two big wins in a row as it pursues innovation. After securing US approval for its BTK inhibitor zanubrutinib for mantle cell lymphoma, its PD-1 inhibitor has sailed through a technical review in China.
You may also be interested in...
BeiGene Is Keeping The Faith In IO/IO Combinations
Global head of R&D Lai Wang talked to Scrip about his expectations for a PD-1/TIGIT combination and remaining confident about the potential of IO/IO combinations in cancer despite disappointments.
SEC Puts US-Listed Chinese Biopharma Firms On Notice To Comply With 2020 Law
Chinese companies publicly traded in the US – including BeiGene, HutchMed and Zai Lab – have three years to switch to accounting firms that can be investigated by the US government, or two years if a pending amendment is adopted.
SEC Puts US-Listed Chinese Biopharma Firms On Notice To Comply With 2020 Law
Chinese companies publicly traded in the US – including BeiGene, HutchMed and Zai Lab – have three years to switch to accounting firms that can be investigated by the US government, or two years if a pending amendment is adopted.